Image 1 of 1
The Food and Drug Administration has not evaluated these statements. This product is not intended to diagnose, treat, cure, or prevent any disease or medical condition. For laboratory research use only. Not for human consumption. CJC-1295 (without DAC) + Ipamorelin is a research peptide blend containing 10 mg per vial (typically 5 mg CJC-1295 without DAC + 5 mg Ipamorelin). This combination pairs two distinct peptide compounds commonly studied for their complementary interaction with growth hormone signaling pathways. CJC-1295 (without DAC) is a modified growth hormone–releasing hormone (GHRH) analog designed for shorter activity than the DAC-modified version, making it useful in research involving pulsatile growth hormone release. Ipamorelin is a selective growth hormone secretagogue (GHS) that acts as a ghrelin receptor agonist and is frequently investigated for its receptor specificity and signaling characteristics. Together, this peptide blend is utilized in laboratory research to evaluate coordinated activation of growth hormone–related pathways, receptor interactions, pharmacokinetics, and peptide stability. Studies may compare the combined effects of GHRH analogs and ghrelin receptor agonists while examining distribution, clearance, and signaling dynamics in controlled research models. This product is manufactured for research purposes only and is intended exclusively for qualified laboratory professionals conducting scientific investigations
